# US 2010/0168110 A1 · Novel Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168110 A1
- Document ID: US20100168110A1
- Status: Published application
- Kind: A1
- Application number: 12/224,168
- Filed: 2008-06-02
- Published: 2010-07-01
- Earliest claimed: 2007-06-06
- Assignees: Torrent Pharmaceuticals Limited
- Inventors: Laxmikant Chhipa; Shitalkumar Zambad; Ramesh Gupta; Davinder Tuli; Ashok Kasundra; Siralee Munshi; M. Amir Siddiqui; Subrat Kumar Bhattamisra; C. Dutt; Vijay Chauthaiwale
- Web page: https://patentgrep.com/patent/US20100168110A1

## CPC

- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/16: for decreasing, blocking or antagonising the activity of the thyroid hormones
- A61P 5/48: of the pancreatic hormones
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/24: Antidepressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 231/18: One oxygen or sulfur atom
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

## Claims

### Claim 1

A compound of formula (I)
Wherein, R1 and R3 is same or different, and is independently selected from H, (C1-C6)alkyl, (C3-C7) cycloalkyl, halo, CN, CF3, —O—(C1-C6)alkyl, —CO2—(C1-C6)alkyl, COOH, —CONH—(C1-C6)alkyl, —CONH-aryl, —NH2, —CONH—R6, —CONR5, —C1-C3alkyl-aryl, —(C1-C3)alkyl-R6, —NH—(C1-C6)alkyl, —NHaryl, —NH—SO2—(C1-C6)alkyl, —CH2—NH—(C1-C6)alkyl, —CH2—O—(C1-C6)alkyl, —C1-C3alkyl-NR5, R6, R7, wherein C1-C6alkyl and C3-C7 cycloalkyl is optionally substituted with one or more substituents selected from (C1-C6)alkyl, halo, cyano, —OH, oxo, —COOH, —O—(C1-C6)alkyl, —O-benzyl, —COO—(C1-C6)alkyl, —CONH—(C1-C6)alkyl, —CONR5, —CONH-aryl, —CONH-heteroaryl or —CH2NR5;
R2 is selected from (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)alkenyl, (C3-C6)alkynyl, —C(O)—(C1-C3)alkyl-COOH, —(C1-C3)alkyl-COOH, —C(O)—(C1-C3)alkyl-COO-alkyl, —C(O)—C(O)O—(C1-C6)alkyl, —C(O)—(C1-C3)alkyl-NH—(C1-C6)alkyl, —C(O)—O—(C1-C6)alkyl, —C(O)NR5, —C(O)NH—(C1-C6)alkyl, —C(O)—(C1-C3)alkylaryl, —C(O)—(C1-C3)alkyl-R6, R6, R7, wherein said (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)alkenyl, (C3-C6)alkynyl being optionally substituted with one or more substituents selected from perhaloalkyl, Oxo, —C(O)OH, —C(O)—O—(C1-C3)alkyl, —C(O)—O—(C1-C3)alky-laryl, —C(O)—O—(C1-C3)alkyl-R6, —CONH2, —CONH(C1-C3)alkyl, —C(O)NH-aryl, —C(O)NH—R6, —CONR5—CONHNH2, —C(═NH)NH—(C1-C6)alkyl, —C(═NH)NH2, C(═NH)NHOH, —C(O)—R8, —C(O)NHSO2(C1-C6)alkyl, —C(O)NHSO2-aryl, —C(O)NHOH, —C(O)NHSO2—R6, —C(O)NHNH—(C1-C6)alkyl, —C(O)NHNH-aryl, —CONH—(C1-C2)alkyl-aryl, —C(O)NH—(C1-C2)alkyl-R6, —CH2NR5, —NH2, —NH—(C1-C6)alkyl, —NH—C(O)—O—(C1-C3)alkyl, —NH—C(O)—(C1-C3)alkyl, —NHC(O)-aryl, —NHC(O)—(C1-C3)alkylaryl, —NHC(O)—R6, —NH—C(O)NR5, —NH—C(O)NH-aryl, —NHC(O)NH—(C1-C6)alkyl, —NHSO2(C1-C6)alkyl, —NH—SO2-aryl, —NH—SO2—R6, halo, cyano, —OH, —O—(C1-C6)alkyl, —O-aryl, —O-heteroaryl, —O—(C1-C2)alkyl-aryl, —SO3H, —SO2NH-aryl, —SO2NH—R6 or —SO2NH—(C1-C6)alkyl, R6 or R7;
R5 together with Nitrogen atom to which it is attached form a saturated or unsaturated (C3-C6) membered ring, which may further contain 1-2 heteroatoms selected from O, N or S and which may be optionally substituted with one or more substituents selected from oxo, —COOH, halo, —OH, —O—(C1-C6)alkyl, or —(C1-C6)alkyl;
R6 is selected from phenyl or 5-8 membered heteroaryl containing 1-4 heteroatoms selected from O, N or S, wherein said heteroaryl or phenyl ring being optionally substituted with one or more substituents selected from halogen, —OH, —O—(C1-C6)alkyl, -perhaloalkyl, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, —SO2(C1-C6)alkyl, cyano, —COOH, —C(O)O—(C1-C6)alkyl, —C(O)O—CH2-aryl, —C(O)O-aryl, —CONH(C1-C3)alkyl, nitro, —NH2, —NH—(C1-C6)alkyl —NHC(O)—(C1-C6)alkyl, —NHC(O)-aryl, —NHSO2(C1-C6)alkyl, —CONH2, —SO2—(C1-C6)alkyl, —NHSO2(C1-C6)alkyl or —COR8;
R7 is a 3-6 membered heterocyclic ring containing 1-4 heteroatom selected from O, N or S, and the said heterocyclic ring being optionally substituted with one or more substituents selected from oxo, halogen, —O—(C1-C6)alkyl, —OH, —CF3, (C1-C6)alkyl, (C3-C6)cycloalkyl, cyano, —COOH, —C(O)O—(C1-C6)alkyl, —C(O)O—CH2-aryl, —C(O)O-aryl, —NH2, —NH—(C1-C6)alkyl, —NHC(O)—(C1-C6)alkyl, —NHC(O)-aryl, —CONH2, —SO2aryl(C1-C6)alkyl, —SO2—(C1-C6)alkyl, —NHSO2(C1-C6)alkyl or —COR8;
R8 is an amino acid which is linked through its nitrogen atom;
Z=O, CH2 or NH;
R4 is selected from P, Q or T
selected from —OH, —O-alkyl, —OSO3H, halogen, —C(O)O—(C1-C6)alkyl, —C(O)NHR8, —OC(O)—(C1-C6)alkyl, —O-perhaloalkyl, —OC(O)O—(C1-C6)alkyl, —CONR5, —NHCO—(C1-C6)alkyl, —NHC(O)—O—(C1-C6)alkyl, —NHC(O)—O-aryl, —NHSO2—(C1-C6)alkyl, —NHSO2-aryl, —NHCONR5 or;
R10 is selected from H, Halogen, (C1-C6)alkyl, alkoxy, aryloxy, —NHCO—(C1-C6)alkyl, —NHSO2—(C1-C6)alkyl or —NH—SO2-aryl;
R11 is —O—(C1-C6)alkyl, —SO2—(C1-C6)alkyl or —SO2-aryl;
G′ is selected from H, halogen or (C1-C6)alkyl;
G″ is selected from hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, halogen, perhaloalkyl, CN, CHO, —(C1-C3)alkylaryl, —(C1-C6)alkyl-O—(C1-C6)alkyl, —CH2R9, —CH2aryl, —CH2NR5, —COOH, —C(O)O(C1-C6)alkyl, —CONH—(C1-C6)alkyl, —CONR5, —SO2NR5, —SO2NH—(C1-C6)alkyl, —SO2NH-aryl;
n may be one or two;
including their pharmaceutically acceptable salts and their hydrates, solvates, atropisomers, regioisomers enantiomers, diastereomers, tautomers, polymorphs and prodrugs thereof with a proviso that:
when R4 is Q then
R2 is other than R6 and R7;
including their pharmaceutically acceptable salts and their hydrates, solvates, atropisomers, regioisomers, enantiomers, diastereomers, tautomers, polymorphs and prodrugs thereof.

### Claim 2 (depends on 1)

The compound as claimed in claim 1, wherein R4 is selected from P or T.

### Claim 3

A compound which is selected from the group consisting of:
1 3-[4-(7-Hydroxy-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
2 3-[4-(1H-Indol-5-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
3 7-[3,5-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-1H-pyrazol-4-yloxy]-indan-4-ol,
4 7-{3,5-Dimethyl-1-[2-(1H-tetrazol-5-yl)-ethyl]-1H-pyrazol-4-yloxy}-indan-4-ol,
5 {2-[(4-(7-Hydroxy-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-acetyl amino}-acetic acid,
6 2-[4-(7-Hydroxy-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-N-(1H-tetrazol-5-yl)-acetamide,
7 3-[4-(7-Hydroxy-indan-4-yloxy)-3-thiophen-2-yl-pyrazol-1-yl]-propionic acid
And 3-[4-(7-Hydroxy-indan-4-yloxy)-5-thiophen-2-yl-pyrazol-1-yl]-propionic acid,
8 7-[1-(1H-Tetrazol-5-ylmethyl)-3-thiophen-2-yl-1H-pyrazol-4-yloxy]-indan-4-ol And 7-[1-(1H-Tetrazol-5-ylmethyl)-5-thiophen-2-yl-1H-pyrazol-4-yloxy]-indan-4-ol,
9 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
10 5-[4-(7-Hydroxy-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-ylmethyl-1H-pyrazol-3-ol
11 2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetic acid,
12 7-[1-(2-Hydroxy-ethyl)-3,5-dimethyl-1H-pyrazol-4-ylmethyl]-5-methyl-indan-4-ol,
13 [4-(1H-Indol-5-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetic acid,
14 3-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
15 7-[3,5-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-1H-pyrazol-4-ylmethyl]-5-methyl-indan-4-ol,
16 7-[3,5-Diisopropyl-1-(1H-tetrazol-5-ylmethyl)-1H-pyrazol-4-ylmethyl]-5-methyl-indan-4-ol,
17 3-[3,5-Dicyclopropyl-4-(7-hydroxy-indan-4-yloxy)-pyrazol-1-yl]-propionic acid,
18 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-diisopropyl-pyrazol-1-yl]-propionic acid,
19 [3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetic acid,
20 3-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-propionic acid,
21 7-[3,5-Diethyl-1-(1H-tetrazol-5-ylmethyl)-1H-pyrazol-4-ylmethyl]-5-methyl-indan-4-ol,
22 [3,5-Dicyclopropyl-4-(7-hydroxy-indan-4-yloxy)-pyrazol-1-yl]-acetic acid,
23 3-[3,5-Diethyl-4-(1H-indol-5-ylmethyl)-pyrazol-1-yl]-propionic acid,
24 2-[4-(1H-Indol-5-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-ethanol,
25 [4-(7-Hydroxy-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-acetic acid,
26 3-[(4-(6-Chloro-7-hydroxy-indan-4-ylmethyl)-3,5-diethyl-pyrazol-1-yl]-propionic acid,
27 [4-(6-Chloro-7-hydroxy-indan-4-ylmethyl)-3,5-diethyl-pyrazol-1-yl]-acetic acid,
28 3-{(4-[7-Hydroxy-6-(pyrrolidine-1-carbonyl)-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-propionic acid,
29 3-[4-(6-Chloro-7-hydroxy-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
30 1-{(2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetyl}-pyrrolidine-2-carboxylic acid,
31 7-[3,5-Dimethyl-1-(1H-tetrazol-5-ylmethyl)-1H-pyrazol-4-yloxy]-5-methyl-indan-4-ol,
32 [4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-diisopropyl-pyrazol-1-yl]-acetic acid,
33 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-N-isopropyl-propionamide,
34 [4-(7-Hydroxy-6-methyl-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-acetic acid,
35 3-[4-(7-Hydroxy-6-methyl-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
36 4-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-butyric acid,
37 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-N-(1H-tetrazol-5-yl)-propionamide,
38 5-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-ylmethyl]-3H-[1,3,4]oxadiazol-2-one,
39 7-{(3,5-Dimethyl-1-[2-(1H-tetrazol-5-yl)-ethyl]-1H-pyrazol-4-ylmethyl}-5-methyl-indan-4-ol,
40 {2-[(4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetylamino}-acetic acid,
41 5-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-ylmethyl]-1H-pyrazol-3-ol,
42 5-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-ylmethyl]-3H-[1,3,4]oxadiazol-2-one,
43 5-{2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-ethyl}-3H-[1,3,4]oxadiazol-2-one,
44 {2-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetylamino}-acetic acid,
45 6-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-ylmethyl]-2-methyl-3H-pyrimidin-4-one,
46 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-ylmethyl]-[1,2,4]oxadiazol-5-ol,
47 7-(1-Benzyl-3,5-dimethyl-1H-pyrazol-4-ylmethyl)-5-methyl-indan-4-ol,
48 3-{4-[7-Hydroxy-6-(4-methyl-benzyl)-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-propionic acid,
49 2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
50 3-[4-(7-Hydroxy-6-isopropyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
51 {4-[7-Hydroxy-6-(4-methyl-benzyl)-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-acetic acid,
52 3-{4-[6-(4-Fluoro-benzyl)-7-hydroxy-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-propionic acid,
53 {4-[6-(4-Fluoro-benzyl)-7-hydroxy-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-acetic acid,
54 Sodium salt of 4-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-butyric acid,
55 Magnesium salt of 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
56 Sodium salt of 3-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
57 3-{3,5-Diethyl-4-[6-(4-fluoro-benzyl)-7-hydroxy-indan-4-ylmethyl]-pyrazol-1-yl}-propionic acid,
58 3-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-3-oxo-propionic acid ethyl ester,
59 [3,5-Diethyl-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetic acid hydrazide,
60 N-Hydroxy-2-[4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetamidine,
61 [4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-oxo-acetic acid ethyl ester,
62 [4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-morpholin-4-yl-methanone,
63 1-(4-Chloro-phenyl)-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-1H-pyrazole,
64 2-(4-Methanesulfonyl-phenyl)-1-[4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-ethanone,
65 4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazole-1-carboxylic acid ethyl ester,
65 Propane-2-sulfonic acid {3-[(4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionyl}-amide,
67 3-[5-Ethoxy-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3-methyl-pyrazol-1-yl]-propionic acid
OR
3-[3-Ethoxy-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-5-methyl-pyrazol-1-yl]-propionic acid,
68 [4-(7-Hydroxy-3,6-dimethyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetic acid,
69 2-[4-(7-Hydroxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-ylmethyl]-pentanedioic acid,
70 [4-(7-Methoxy-2,2,6-trimethyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetic acid,
71 N-{2-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-ethyl}-acetamide,
72 N-{2-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-ethyl}-methanesulfonamide,
73 4-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-1-(toluene-4-sulfonyl)-piperidine,
74 {3,5-Diethyl-4-[6-(4-fluoro-benzyl)-7-hydroxy-indan-4-ylmethyl]-pyrazol-1-yl}-acetic acid,
75 3-[(4-[7-Methoxy-6-(4-methoxy-phenyl)-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
76 2-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-N-isopropyl-acetamide,
77 3-[4-(7-Ethoxycarbonyloxy-6-methyl-indan-4-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-propionic acid methyl ester,
78 Sodium salt of [3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetic acid,
79 3-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-3-methyl-5-rifluoromethyl-pyrazol-1-yl]-propionic acid And 3-[4-(7-Methoxy-6-methyl-indan-4-ylmethyl)-5-methyl-3-rifluoromethyl-pyrazol-1-yl]-propionic acid,
80 [4-(4-Hydroxy-3-methyl-5,6,7,8-tetrahydro-naphthalen-1-ylmethyl)-3,5-dimethyl-pyrazol-1-yl]-acetic acid,
81 [4-(7-Chloro-indan-4-yloxy)-3-thiophen-2-yl-pyrazol-1-yl]-acetic acid And [4-(7-Chloro-indan-4-yloxy)-5-thiophen-2-yl-pyrazol-1-yl]-acetic acid,
82 {4-[7-Methoxy-6-methyl-2-(4-nitro-phenoxy)-indan-4-ylmethyl]-3,5-dimethyl-pyrazol-1-yl}-acetic acid,
83 [5-Amino-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-3-(4-methoxy-phenyl)-pyrazol-1-yl]-acetic acid
And [3-Amino-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-5-(4-methoxy-phenyl)-pyrazol-1-yl]-acetic acid,
84 2-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-N-(1H-tetrazol-5-yl)-acetamide,
85 1-Carboxymethyl-5-(5-chloro-thiophen-2-yl)-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-1H-pyrazole-3-carboxylic acid
And
2-Carboxymethyl-5-(5-chloro-thiophen-2-yl)-4-(7-methoxy-6-methyl-indan-4-ylmethyl)-2H-pyrazole-3-carboxylic acid,
86 3-[4-(1H-Indol-5-yloxy)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
87 [4-(1H-Indol-5-yloxy)-3,5-dimethyl-pyrazol-1-yl]-acetic acid,
89 2-[4-(7-Hydroxy-indan-4-yloxy)-3,5-dimethyl-pyrazol-1-yl]-propionic acid,
89 1-{2-[3,5-Diethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetyl}-pyrrolidine-2-carboxylic acid,
90 [3,5-Diethyl-4-(7-hydroxy-6-pyrrolidin-1-ylmethyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetic acid,
91 3-[3,5-Diethyl-4-(7-hydroxy-6-pyrrolidin-1-ylmethyl-indan-4-ylmethyl)-pyrazol-1-yl]-propionic acid,
92 3-[3,5-Diethyl-4-(7-methoxy-6-methoxymethyl-indan-4-ylmethyl)-pyrazol-1-yl]-propionic acid,
93 {3,5-Diethyl-4-[7-hydroxy-6-(pyrrolidine-1-carbonyl)-indan-4-ylmethyl]-pyrazol-1-yl}-acetic acid,
94 [3,5-Diethyl-4-(7-methoxy-6-methoxymethyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetic acid,
95 3-{3,5-Diethyl-4-[7-hydroxy-6-(pyrrolidine-1-carbonyl)-indan-4-ylmethyl]-pyrazol-1-yl}-propionic acid,
and
96 N-(4-Chloro-phenyl)-2-[3,5-d]ethyl-4-(7-hydroxy-6-methyl-indan-4-ylmethyl)-pyrazol-1-yl]-acetamide including their pharmaceutically acceptable salts and their hydrates, solvates, atropisomers, regioisomers, enantiomers, diastereomers, tautomers, polymorphs and prodrugs thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition comprising a therapeutically effective amount of one or more compound as claimed in claim 1, optionally in association with a pharmaceutically acceptable, diluents or carriers.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The method of treating obesity in a living mammalian organism, including human being, comprising administering to the said living mammalian organism in need thereof, a therapeutically effective amount of a compound as claimed in claim 1.

### Claim 12 (depends on 1)

The method of ameliorating insulin resistance and/or preventing or delaying progression to frank diabetes in a living mammalian organism, including human being, comprising administering to the said living mammalian organism in need thereof, a therapeutically effective amount of a compound as claimed in claim 1.

### Claim 13 (depends on 1)

The method of preventing and treating dyslipidemia in a living mammalian organism, including human being, comprising administering to the said living mammalian organism in need thereof, a therapeutically effective amount of a compound as claimed in claim 1.

### Claim 14 (depends on 1)

The method of preventing and treating metabolic syndrome in a living mammalian organism, including human being, comprising administering to the said living mammalian organism in need thereof, a therapeutically effective amount of a compound as claimed in claim 1.

### Claim 15 (depends on 1)

The method of preventing and treating a disease or disorder associated with inappropriate thyroid hormone activity in a living mammalian organism, including human being, comprising administering to the said living mammalian organism in need thereof, a therapeutically effective amount of a compound as claimed in claim 1.

### Claim 16 (depends on 15)

The method as claimed in claim 15 wherein said diseases or disorders are selected from 1) The conditions associated with a disease or disorder associated with excessive fat accumulation, altered mitochondrial function, 2) lipid disorders caused by an imbalance of blood or tissue lipid levels 3) impaired glucose tolerance 4) type II diabetes 5) replacement therapy in elderly subjects with hypothyroidism 6) depression 7) cardiovascular diseases and 8) skin disorders.

### Claim 17

A method for treating a living mammalian organism, including human being for disease conditions associated with inappropriate thyroid hormone activity selected from obesity, insulin resistance, dyslipidemia, metabolic syndrome, type II diabetes, replacement therapy in elderly subjects with hypothyroidism, depression, cardiovascular diseases and skin disorders comprising administration of a therapeutically effective amount of a compound of formula:
Wherein, R1 and R3 is same or different, and is independently selected from H, (C1-C6)alkyl, (C3-C7)cycloalkyl, halo, CN, CF3, —O—(C1-C6)alkyl, —CO2—(C1-C6)alkyl, COOH, —CONH—(C1-C6)alkyl, —CONH-aryl, —NH2, —CONH—R6, —CONR5, —C1-C3alkyl-aryl, —(C1-C3)alkyl-R6, —NH—(C1-C6)alkyl, —NHaryl, —NH—SO2—(C1-C6)alkyl, —CH2—NH—(C1-C6)alkyl, —CH2—O—(C1-C6)alkyl, —C1-C3alkyl-NR5, R6, R7, wherein C1-C6alkyl and C3-C7 cycloalkyl is optionally substituted with one or more substituents selected from (C1-C6)alkyl, halo, cyano, —OH, oxo, —COOH, —O—(C1-C6)alkyl, —O-benzyl, —COO—(C1-C6)alkyl, —CONH—C1-C6)alkyl, —CONR5, —CONH-aryl, —CONH-heteroaryl or —CH2NR5;
R2 is selected from (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)alkenyl, (C3-C6)alkynyl, —C(O)—(C1-C3)alkyl-COOH, —(C1-C3)alkyl-COOH, —C(O)—(C1-C3)alkyl-COO-alkyl, —C(O)—C(O)O—(C1-C6)alkyl, —C(O)—(C1-C3)alkyl-NH—(C1-C6)alkyl, —C(O)—O—(C1-C6)alkyl, —C(O)NR5, —C(O)NH—(C1-C6)alkyl, —C(O)—(C1-C3)alkylaryl, —C(O)—(C1-C3)alkyl-R6, R6, R7, wherein said (C1-C6)alkyl, (C3-C6)cycloalkyl, (C3-C6)alkenyl, (C3-C6)alkynyl being optionally substituted with one or more substituents selected from perhaloalkyl, Oxo, —C(O)OH, —C(O)—O—(C1-C3)alkyl, —C(O)—O—(C1-C3)alky-laryl, —C(O)—O—(C1-C3)alkyl-R6, —CONH2, —CONH(C1-C3)alkyl, —C(O)NH-aryl, —C(O)NH—R6, —CONR5—CONHNH2, —C(═NH)NH—(C1-C6)alkyl, —C(═NH)NH2, C(═NH)NHOH, —C(O)—R8, —C(O)NHSO2 (C1-C6)alkyl, —C(O)NHSO2-aryl, —C(O)NHOH, —C(O)NHSO2—R6, —C(O)NHNH—(C1-C6)alkyl, —C(O)NHNH-aryl, —CONH—(C1-C2)alkyl-aryl, —C(O)NH—(C1-C2)alkyl-R6, —CH2NR5, —NH2, —NH—(C1-C6)alkyl, —NH—C(O)—O—(C1-C3)alkyl, —NH—C(O)—(C1-C3)alkyl, —NHC(O)-aryl, —NHC(O)—(C1-C3)alkylaryl, —NHC(O)—R6, —NH—C(O)NR5, —NH—C(O)NH-aryl, —NHC(O)NH—(C1-C6)alkyl, —NHSO2(C1-C6)alkyl, —NH—SO2-aryl, —NH—SO2—R6, halo, cyano, —OH, —O—(C1-C6)alkyl, —O-aryl, —O-heteroaryl, —O—(C1-C2)alkyl-aryl, —SO3H, —SO2NH-aryl, —SO2NH—R6 or —SO2NH—(C1-C6)alkyl, R6 or R7;
R5 together with Nitrogen atom to which it is attached form a saturated or unsaturated (C3-C6) membered ring, which may further contain 1-2 heteroatoms selected from O, N or S and which may be optionally substituted with one or more substituents selected from oxo, —COOH, halo, —OH, —O—(C1-C6)alkyl, or —(C1-C6)alkyl;
R6 is selected from phenyl or 5-8 membered heteroaryl containing 1-4 heteroatoms selected from O, N or S, wherein said heteroaryl or phenyl ring being optionally substituted with one or more substituents selected from halogen, —OH, —O—(C1-C6)alkyl, -perhaloalkyl, —(C1-C6)alkyl, —(C3-C6)cycloalkyl, —SO2(C1-C6)alkyl, cyano, —COOH, —C(O)O—(C1-C6)alkyl, —C(O)O—CH2-aryl, —C(O)O-aryl, —CONH(C1-C3)alkyl, nitro, —NH2, —NH—(C1-C6)alkyl, —NHC(O)—(C1-C6)alkyl, —NHC(O)-aryl, —NHSO2(C1-C6)alkyl, —CONH2, —SO2—(C1-C6)alkyl, —NHSO2(C1-C6)alkyl or —COR8;
R7 is a 3-6 membered heterocyclic ring containing 1-4 heteroatom selected from O, N or S, and the said heterocyclic ring being optionally substituted with one or more substituents selected from oxo, halogen, —O—(C1-C6)alkyl, —OH, —CF3, (C1-C6)alkyl, (C3-C6)cycloalkyl, cyano, —COOH, —C(O)O—(C1-C6)alkyl, —C(O)O—CH2-aryl, —C(O)O-aryl, —NH2, —NH—(C1-C6)alkyl, —NHC(O)—(C1-C6)alkyl, —NHC(O)-aryl, —CONH2, —SO2aryl(C1-C6)alkyl, —SO2—(C1-C6)alkyl, —NHSO2(C1-C6)alkyl or —COR8;
R8 is an amino acid which is linked through its nitrogen atom;
Z=O, CH2 or NH;
R4 is selected from P, Q or T
R9 is selected from —OH, —O-alkyl, —OSO3H, halogen, —C(O)O—(C1-C6)alkyl, —C(O)NHR8, —OC(O)—(C1-C6)alkyl, —O-perhaloalkyl, —OC(O)O—(C1-C6)alkyl, —CONR5, —NHCO—(C1-C6)alkyl, —NHC(O)—O—(C1-C6)alkyl, —NHC(O)—O-aryl, —NHSO2—(C1-C6)alkyl, —NHSO2-aryl, —NHCONR5 or;
R10 is selected from H, Halogen, (C1-C6)alkyl, alkoxy, aryloxy, —NHCO—(C1-C6)alkyl, —NHSO2—(C1-C6)alkyl or —NH—SO2-aryl;
R11 is H, (C1-C6)alkyl, —CO—(C1-C6)alkyl, —SO2-(C1-C6)alkyl or —SO2-aryl;
G′ is selected from H, halogen or (C1-C6)alkyl;
G″ is selected from hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, aryl, halogen, perhaloalkyl, CN, CHO, —(C1-C3)alkylaryl, —(C1-C6)alkyl-O—(C1-C6)alkyl, —CH2R9, —CH2aryl, —CH2NR5, —COOH, —C(O)O(C1-C6)alkyl, —CONH—(C1-C6)alkyl, —CONR5, —SO2NR5, —SO2NH—(C1-C6)alkyl, —SO2NH-aryl;
n may be one or two;
including their pharmaceutically acceptable salts and their hydrates, solvates, atropisomers, regioisomers, enantiomers, diastereomers, tautomers, polymorphs and prodrugs thereof.

### Claim 18 (depends on 1)

The process for the preparation of a compound as claimed in claim 1, which comprises:
(i) reacting a compound of formula (II)
with compound of formula
R2—Y
Wherein Y is a leaving group preferably halogen in the presence of suitable base in suitable solvent or;
(ii) reacting a compound of formula (III) or (IX)
with hydrazine hydrate or suitably substituted hydrazine of formula
R2NH NH2
or;
(iii) reacting a compound of formula (XIII)
R4—CHO XIII
with a compound of formula (V)
in presence of suitable base in suitable solvent followed by reduction with suitable reducing agent;
or,
(iv) reacting a compound of formula (XV)
R4—CH2Y XV
wherein Y is leaving group preferably halogen with a compound of formula (V)
in presence of suitable base in suitable solvent or;
(v) reacting a compound of formula (IV)
With a compound R4OH or R4NH2 in presence of base;
Wherein R1 R2, R3 and R4 are as defined in claim 1.

### Claim 19

(canceled)

### Claim 20 (depends on 3)

The pharmaceutical composition comprising a therapeutically effective amount of one or more compound as claimed in claim 3, optionally in association with a pharmaceutically acceptable, diluents or carriers.

### Claim 21 (depends on 3)

The method of treating obesity in a living mammalian organism, including human being, comprising administering to the said living mammalian organism in need thereof, a therapeutically effective amount of a compound as claimed in claim 3.

### Claim 22 (depends on 3)

The method of ameliorating insulin resistance and/or preventing or delaying progression to frank diabetes in a living mammalian organism, including human being, comprising administering to the said living mammalian organism in need thereof, a therapeutically effective amount of a compound as claimed in claim 3.

### Claim 23 (depends on 3)

The method of preventing and treating dyslipidemia in a living mammalian organism, including human being, comprising administering to the said living mammalian organism in need thereof, a therapeutically effective amount of a compound as claimed in claim 3.

### Claim 24 (depends on 3)

The method of preventing and treating metabolic syndrome in a living mammalian organism, including human being, comprising administering to the said living mammalian organism in need thereof, a therapeutically effective amount of a compound as claimed in claim 3.

### Claim 25 (depends on 3)

The method of preventing and treating a disease or disorder associated with inappropriate thyroid hormone activity in a living mammalian organism, including human being, comprising administering to the said living mammalian organism in need thereof, a therapeutically effective amount of a compound as claimed in claim 3.

### Claim 26 (depends on 25)

The method as claimed in claim 25 wherein said diseases or disorders are selected from 1) The conditions associated with a disease or disorder associated with excessive fat accumulation, altered mitochondrial function, 2) lipid disorders caused by an imbalance of blood or tissue lipid levels 3) impaired glucose tolerance 4) type II diabetes 5) replacement therapy in elderly subjects with hypothyroidism 6) depression 7) cardiovascular diseases and 8) skin disorders.
